| Double-blind Period,* ABA Group (1 yr; n = 433) | Cumulative Period,† All ABA-treated Patients (5 yrs; n = 594) |
---|
Incidence rate (events/100 patient-yrs) |
---|
Adverse events | 303.4 | 242.32 |
Serious adverse events | 17.7 | 13.87 |
Infections | 90.5 | 67.14 |
Serious infections | 4.2 | 2.84 |
Malignancies | 1.7 | 1.45 |
Autoimmune events | 2.5 | 0.99 |